These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31285308)

  • 1. Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea.
    Mok J; Kang H; Koh WJ; Jhun BW; Yim JJ; Kwak N; Lee T; Kang B; Jeon D
    Eur Respir J; 2019 Nov; 54(5):. PubMed ID: 31285308
    [No Abstract]   [Full Text] [Related]  

  • 2. Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
    Kuksa L; Barkane L; Hittel N; Gupta R
    Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29122917
    [No Abstract]   [Full Text] [Related]  

  • 3. Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea.
    Mok J; Kang H; Hwang SH; Park JS; Kang B; Lee T; Koh WJ; Yim JJ; Jeon D
    J Antimicrob Chemother; 2018 Feb; 73(2):503-508. PubMed ID: 29069496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
    Skripconoka V; Danilovits M; Pehme L; Tomson T; Skenders G; Kummik T; Cirule A; Leimane V; Kurve A; Levina K; Geiter LJ; Manissero D; Wells CD
    Eur Respir J; 2013 Jun; 41(6):1393-400. PubMed ID: 23018916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
    Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Access to new drugs and the global drug-resistant TB crisis: a case series from KwaZulu-Natal, South Africa.
    Master I; Furin J
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):985-7. PubMed ID: 27287655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use.
    Hafkin J; Hittel N; Martin A; Gupta R
    Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28751415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six-Month Response to Delamanid Treatment in MDR TB Patients.
    Hewison C; Ferlazzo G; Avaliani Z; Hayrapetyan A; Jonckheere S; Khaidarkhanova Z; Mohr E; Sinha A; Skrahina A; Vambe D; Vasilyeva I; Lachenal N; Varaine F
    Emerg Infect Dis; 2017 Oct; 23(10):1746-8. PubMed ID: 28767036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
    Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
    Maryandyshev A; Pontali E; Tiberi S; Akkerman O; Ganatra S; Sadutshang TD; Alffenaar JW; Amale R; Mullerpattan J; Topgyal S; Udwadia ZF; Centis R; D'Ambrosio L; Sotgiu G; Migliori GB
    Emerg Infect Dis; 2017 Oct; 23(10):1718-21. PubMed ID: 28758888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China.
    Zhang Q; Liu Y; Tang S; Sha W; Xiao H
    Cell Biochem Biophys; 2013; 67(3):957-63. PubMed ID: 23546935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
    BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
    Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS; Jeong BH; Koh WJ
    Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis: A case report and review of the literature.
    Esposito S; Bosis S; Tadolini M; Bianchini S; Migliori GB; Principi N
    Medicine (Baltimore); 2016 Nov; 95(46):e5347. PubMed ID: 27861363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ; Gibbert J; Wirth D; Diel R
    Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.